Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Melanoma plasticity and phenotypic diversity: therapeutic barriers and opportunities.

Rambow F, Marine JC, Goding CR.

Genes Dev. 2019 Oct 1;33(19-20):1295-1318. doi: 10.1101/gad.329771.119. Review.

PMID:
31575676
2.

The lncRNA NEAT1_1 is seemingly dispensable for normal tissue homeostasis and cancer cell growth.

Adriaens C, Rambow F, Bervoets G, Silla T, Mito M, Chiba T, Hiroshi A, Hirose T, Nakagawa S, Jensen TH, Marine JC.

RNA. 2019 Sep 24. pii: rna.071456.119. doi: 10.1261/rna.071456.119. [Epub ahead of print]

PMID:
31551298
3.

Dynamic reversal of random X-Chromosome inactivation during iPSC reprogramming.

Janiszewski A, Talon I, Chappell J, Collombet S, Song J, De Geest N, To SK, Bervoets G, Marin-Bejar O, Provenzano C, Vanheer L, Marine JC, Rambow F, Pasque V.

Genome Res. 2019 Oct;29(10):1659-1672. doi: 10.1101/gr.249706.119. Epub 2019 Sep 12.

4.

Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia.

Bell CC, Fennell KA, Chan YC, Rambow F, Yeung MM, Vassiliadis D, Lara L, Yeh P, Martelotto LG, Rogiers A, Kremer BE, Barbash O, Mohammad HP, Johanson TM, Burr ML, Dhar A, Karpinich N, Tian L, Tyler DS, MacPherson L, Shi J, Pinnawala N, Yew Fong C, Papenfuss AT, Grimmond SM, Dawson SJ, Allan RS, Kruger RG, Vakoc CR, Goode DL, Naik SH, Gilan O, Lam EYN, Marine JC, Prinjha RK, Dawson MA.

Nat Commun. 2019 Jun 20;10(1):2723. doi: 10.1038/s41467-019-10652-9.

5.

Targeting the Sphingosine 1-Phosphate Axis Exerts Potent Antitumor Activity in BRAFi-Resistant Melanomas.

Garandeau D, Noujarède J, Leclerc J, Imbert C, Garcia V, Bats ML, Rambow F, Gilhodes J, Filleron T, Meyer N, Brayer S, Arcucci S, Tartare-Deckert S, Ségui B, Marine JC, Levade T, Bertolotto C, Andrieu-Abadie N.

Mol Cancer Ther. 2019 Feb;18(2):289-300. doi: 10.1158/1535-7163.MCT-17-1141. Epub 2018 Nov 27.

PMID:
30482853
6.

Sustained activation of the Aryl hydrocarbon Receptor transcription factor promotes resistance to BRAF-inhibitors in melanoma.

Corre S, Tardif N, Mouchet N, Leclair HM, Boussemart L, Gautron A, Bachelot L, Perrot A, Soshilov A, Rogiers A, Rambow F, Dumontet E, Tarte K, Bessede A, Guillemin GJ, Marine JC, Denison MS, Gilot D, Galibert MD.

Nat Commun. 2018 Nov 14;9(1):4775. doi: 10.1038/s41467-018-06951-2.

7.

Dabrafenib plus trametinib in BRAF K601E-mutant melanoma.

Rogiers A, Thomas D, Vander Borght S, van den Oord JJ, Bechter O, Dewaele M, Rambow F, Marine JC, Wolter P.

Br J Dermatol. 2019 Feb;180(2):421-422. doi: 10.1111/bjd.17250. Epub 2018 Nov 22. No abstract available.

PMID:
30248172
8.

Toward Minimal Residual Disease-Directed Therapy in Melanoma.

Rambow F, Rogiers A, Marin-Bejar O, Aibar S, Femel J, Dewaele M, Karras P, Brown D, Chang YH, Debiec-Rychter M, Adriaens C, Radaelli E, Wolter P, Bechter O, Dummer R, Levesque M, Piris A, Frederick DT, Boland G, Flaherty KT, van den Oord J, Voet T, Aerts S, Lund AW, Marine JC.

Cell. 2018 Aug 9;174(4):843-855.e19. doi: 10.1016/j.cell.2018.06.025. Epub 2018 Jul 12.

9.

Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy.

Talebi A, Dehairs J, Rambow F, Rogiers A, Nittner D, Derua R, Vanderhoydonc F, Duarte JAG, Bosisio F, Van den Eynde K, Nys K, Pérez MV, Agostinis P, Waelkens E, Van den Oord J, Fendt SM, Marine JC, Swinnen JV.

Nat Commun. 2018 Jun 27;9(1):2500. doi: 10.1038/s41467-018-04664-0.

10.

Codon-specific translation reprogramming promotes resistance to targeted therapy.

Rapino F, Delaunay S, Rambow F, Zhou Z, Tharun L, De Tullio P, Sin O, Shostak K, Schmitz S, Piepers J, Ghesquière B, Karim L, Charloteaux B, Jamart D, Florin A, Lambert C, Rorive A, Jerusalem G, Leucci E, Dewaele M, Vooijs M, Leidel SA, Georges M, Voz M, Peers B, Büttner R, Marine JC, Chariot A, Close P.

Nature. 2018 Jun;558(7711):605-609. doi: 10.1038/s41586-018-0243-7. Epub 2018 Jun 20.

PMID:
29925953
11.

The Endosomal Protein CEMIP Links WNT Signaling to MEK1-ERK1/2 Activation in Selumetinib-Resistant Intestinal Organoids.

Duong HQ, Nemazanyy I, Rambow F, Tang SC, Delaunay S, Tharun L, Florin A, Büttner R, Vandaele D, Close P, Marine JC, Shostak K, Chariot A.

Cancer Res. 2018 Aug 15;78(16):4533-4548. doi: 10.1158/0008-5472.CAN-17-3149. Epub 2018 Jun 18.

12.

Mouse Cutaneous Melanoma Induced by Mutant BRaf Arises from Expansion and Dedifferentiation of Mature Pigmented Melanocytes.

Köhler C, Nittner D, Rambow F, Radaelli E, Stanchi F, Vandamme N, Baggiolini A, Sommer L, Berx G, van den Oord JJ, Gerhardt H, Blanpain C, Marine JC.

Cell Stem Cell. 2017 Nov 2;21(5):679-693.e6. doi: 10.1016/j.stem.2017.08.003. Epub 2017 Oct 12.

13.

SCENIC: single-cell regulatory network inference and clustering.

Aibar S, González-Blas CB, Moerman T, Huynh-Thu VA, Imrichova H, Hulselmans G, Rambow F, Marine JC, Geurts P, Aerts J, van den Oord J, Atak ZK, Wouters J, Aerts S.

Nat Methods. 2017 Nov;14(11):1083-1086. doi: 10.1038/nmeth.4463. Epub 2017 Oct 9.

14.

A non-coding function of TYRP1 mRNA promotes melanoma growth.

Gilot D, Migault M, Bachelot L, Journé F, Rogiers A, Donnou-Fournet E, Mogha A, Mouchet N, Pinel-Marie ML, Mari B, Montier T, Corre S, Gautron A, Rambow F, El Hajj P, Ben Jouira R, Tartare-Deckert S, Marine JC, Felden B, Ghanem G, Galibert MD.

Nat Cell Biol. 2017 Nov;19(11):1348-1357. doi: 10.1038/ncb3623. Epub 2017 Oct 9.

15.

The tumour suppressor, miR-137, inhibits malignant melanoma migration by targetting the TBX3 transcription factor.

Peres J, Kwesi-Maliepaard EM, Rambow F, Larue L, Prince S.

Cancer Lett. 2017 Oct 1;405:111-119. doi: 10.1016/j.canlet.2017.07.018. Epub 2017 Jul 28.

PMID:
28757416
16.

Comparative oncogenomics identifies tyrosine kinase FES as a tumor suppressor in melanoma.

Olvedy M, Tisserand JC, Luciani F, Boeckx B, Wouters J, Lopez S, Rambow F, Aibar S, Thienpont B, Barra J, Köhler C, Radaelli E, Tartare-Deckert S, Aerts S, Dubreuil P, van den Oord JJ, Lambrechts D, De Sepulveda P, Marine JC.

J Clin Invest. 2017 Jun 1;127(6):2310-2325. doi: 10.1172/JCI91291. Epub 2017 May 2.

17.

Downregulation of sphingosine kinase-1 induces protective tumor immunity by promoting M1 macrophage response in melanoma.

Mrad M, Imbert C, Garcia V, Rambow F, Therville N, Carpentier S, Ségui B, Levade T, Azar R, Marine JC, Diab-Assaf M, Colacios C, Andrieu-Abadie N.

Oncotarget. 2016 Nov 1;7(44):71873-71886. doi: 10.18632/oncotarget.12380.

18.

Chromatin-Bound MDM2 Regulates Serine Metabolism and Redox Homeostasis Independently of p53.

Riscal R, Schrepfer E, Arena G, Cissé MY, Bellvert F, Heuillet M, Rambow F, Bonneil E, Sabourdy F, Vincent C, Ait-Arsa I, Levade T, Thibaut P, Marine JC, Portais JC, Sarry JE, Le Cam L, Linares LK.

Mol Cell. 2016 Jun 16;62(6):890-902. doi: 10.1016/j.molcel.2016.04.033. Epub 2016 Jun 2.

19.

Regulation of Melanoma Progression through the TCF4/miR-125b/NEDD9 Cascade.

Rambow F, Bechadergue A, Luciani F, Gros G, Domingues M, Bonaventure J, Meurice G, Marine JC, Larue L.

J Invest Dermatol. 2016 Jun;136(6):1229-1237. doi: 10.1016/j.jid.2016.02.803. Epub 2016 Mar 9.

20.

Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth.

Dewaele M, Tabaglio T, Willekens K, Bezzi M, Teo SX, Low DH, Koh CM, Rambow F, Fiers M, Rogiers A, Radaelli E, Al-Haddawi M, Tan SY, Hermans E, Amant F, Yan H, Lakshmanan M, Koumar RC, Lim ST, Derheimer FA, Campbell RM, Bonday Z, Tergaonkar V, Shackleton M, Blattner C, Marine JC, Guccione E.

J Clin Invest. 2016 Jan;126(1):68-84. doi: 10.1172/JCI82534. Epub 2015 Nov 23.

21.

New Functional Signatures for Understanding Melanoma Biology from Tumor Cell Lineage-Specific Analysis.

Rambow F, Job B, Petit V, Gesbert F, Delmas V, Seberg H, Meurice G, Van Otterloo E, Dessen P, Robert C, Gautheret D, Cornell RA, Sarasin A, Larue L.

Cell Rep. 2015 Oct 27;13(4):840-853. doi: 10.1016/j.celrep.2015.09.037. Epub 2015 Oct 17.

22.

A caveolin-dependent and PI3K/AKT-independent role of PTEN in β-catenin transcriptional activity.

Conde-Perez A, Gros G, Longvert C, Pedersen M, Petit V, Aktary Z, Viros A, Gesbert F, Delmas V, Rambow F, Bastian BC, Campbell AD, Colombo S, Puig I, Bellacosa A, Sansom O, Marais R, Van Kempen LC, Larue L.

Nat Commun. 2015 Aug 26;6:8093. doi: 10.1038/ncomms9093.

23.

Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state.

Verfaillie A, Imrichova H, Atak ZK, Dewaele M, Rambow F, Hulselmans G, Christiaens V, Svetlichnyy D, Luciani F, Van den Mooter L, Claerhout S, Fiers M, Journe F, Ghanem GE, Herrmann C, Halder G, Marine JC, Aerts S.

Nat Commun. 2015 Apr 9;6:6683. doi: 10.1038/ncomms7683.

24.

miR-330-5p targets tyrosinase and induces depigmentation.

Rambow F, Bechadergue A, Saintigny G, Morizot F, Mahé C, Larue L.

J Invest Dermatol. 2014 Nov;134(11):2846-2849. doi: 10.1038/jid.2014.231. Epub 2014 May 26. No abstract available.

25.

β-catenin inhibitor ICAT modulates the invasive motility of melanoma cells.

Domingues MJ, Rambow F, Job B, Papon L, Liu W, Larue L, Bonaventure J.

Cancer Res. 2014 Apr 1;74(7):1983-95. doi: 10.1158/0008-5472.CAN-13-0920. Epub 2014 Feb 10.

26.

Efficient gene expression profiling of laser-microdissected melanoma metastases.

Makhzami S, Rambow F, Delmas V, Larue L.

Pigment Cell Melanoma Res. 2012 Nov;25(6):783-91. doi: 10.1111/pcmr.12013.

PMID:
22934821
27.

Beta-catenin inhibits melanocyte migration but induces melanoma metastasis.

Gallagher SJ, Rambow F, Kumasaka M, Champeval D, Bellacosa A, Delmas V, Larue L.

Oncogene. 2013 Apr 25;32(17):2230-8. doi: 10.1038/onc.2012.229. Epub 2012 Jun 4.

28.

P-Rex1 is required for efficient melanoblast migration and melanoma metastasis.

Lindsay CR, Lawn S, Campbell AD, Faller WJ, Rambow F, Mort RL, Timpson P, Li A, Cammareri P, Ridgway RA, Morton JP, Doyle B, Hegarty S, Rafferty M, Murphy IG, McDermott EW, Sheahan K, Pedone K, Finn AJ, Groben PA, Thomas NE, Hao H, Carson C, Norman JC, Machesky LM, Gallagher WM, Jackson IJ, Van Kempen L, Beermann F, Der C, Larue L, Welch HC, Ozanne BW, Sansom OJ.

Nat Commun. 2011 Nov 22;2:555. doi: 10.1038/ncomms1560.

29.

General strategy to analyse coat colour phenotypes in mice.

Berlin I, Luciani F, Gallagher SJ, Rambow F, Conde-Perez A, Colombo S, Champeval D, Delmas V, Larue L.

Pigment Cell Melanoma Res. 2012 Jan;25(1):117-9. doi: 10.1111/j.1755-148X.2011.00912.x. Epub 2011 Nov 16. No abstract available.

PMID:
22085368
30.

General strategy to analyse melanoma in mice.

Gallagher SJ, Luciani F, Berlin I, Rambow F, Gros G, Champeval D, Delmas V, Larue L.

Pigment Cell Melanoma Res. 2011 Oct;24(5):987-8. doi: 10.1111/j.1755-148X.2011.00907.x. Epub 2011 Sep 29. No abstract available.

PMID:
21955491
31.

Transcriptomic analysis of mouse embryonic skin cells reveals previously unreported genes expressed in melanoblasts.

Colombo S, Champeval D, Rambow F, Larue L.

J Invest Dermatol. 2012 Jan;132(1):170-8. doi: 10.1038/jid.2011.252. Epub 2011 Aug 18.

32.

Thymine DNA glycosylase is essential for active DNA demethylation by linked deamination-base excision repair.

Cortellino S, Xu J, Sannai M, Moore R, Caretti E, Cigliano A, Le Coz M, Devarajan K, Wessels A, Soprano D, Abramowitz LK, Bartolomei MS, Rambow F, Bassi MR, Bruno T, Fanciulli M, Renner C, Klein-Szanto AJ, Matsumoto Y, Kobi D, Davidson I, Alberti C, Larue L, Bellacosa A.

Cell. 2011 Jul 8;146(1):67-79. doi: 10.1016/j.cell.2011.06.020. Epub 2011 Jun 30.

33.

The quest for the melanoma stem cell: still more questions than answers.

Rambow F, Larue L.

Pigment Cell Melanoma Res. 2010 Jun;23(3):307-9. doi: 10.1111/j.1755-148X.2010.00713.x. Epub 2010 Apr 23.

PMID:
20444202
34.

Gene expression signature for spontaneous cancer regression in melanoma pigs.

Rambow F, Piton G, Bouet S, Leplat JJ, Baulande S, Marrau A, Stam M, Horak V, Vincent-Naulleau S.

Neoplasia. 2008 Jul;10(7):714-26, 1 p following 726.

35.

Identification of differentially expressed genes in spontaneously regressing melanoma using the MeLiM swine model.

Rambow F, Malek O, Geffrotin C, Leplat JJ, Bouet S, Piton G, Hugot K, Bevilacqua C, Horak V, Vincent-Naulleau S.

Pigment Cell Melanoma Res. 2008 Apr;21(2):147-61. doi: 10.1111/j.1755-148X.2008.00442.x.

PMID:
18426408
36.

Enhanced T-cell activation and T-cell-dependent IL-2 production by CD83+, CD25high, CD43high human monocyte-derived dendritic cells.

Velten FW, Rambow F, Metharom P, Goerdt S.

Mol Immunol. 2007 Mar;44(7):1544-50. Epub 2006 Oct 4.

PMID:
17023048

Supplemental Content

Loading ...
Support Center